Meguro H, Abe T, Ushijima K, Nonaka C, Shinozaki T, Fujii R
Department of Pediatrics, School of Medicine, Teikyo University.
Jpn J Antibiot. 1990 May;43(5):790-8.
Oral new quinolone, norfloxacin (NFLX, AM-715), was evaluated for its safety, efficacy and pharmacokinetics in children. 1. NFLX was effective in 88.0% of 25 cases infected with Haemophilus influenzae, Pseudomonas aeruginosa, Escherichia coli, Campylobacter jejuni, Staphylococcus aureus including methicillin-resistant strains, and other bacteria. 2. After single oral administration of 50 mg and 100 mg NFLX tablet at fasting, mean peak values of serum concentration were 0.35, 0.48 microgram/ml and T1/2 values were 2.2, 2.7 hours, respectively. 3. No adverse reactions suggestive for arthropathy were encountered with NFLX therapy with daily doses of 4.6-35.7 mg/kg (maximum 600 mg per day) and duration of 3 to 19 days. From these preliminary data, NFLX seems to have a place in the treatment of pediatric infectious diseases.
对新型口服喹诺酮类药物诺氟沙星（NFLX，AM - 715）在儿童中的安全性、疗效和药代动力学进行了评估。1. 在25例感染流感嗜血杆菌、铜绿假单胞菌、大肠杆菌、空肠弯曲菌、包括耐甲氧西林菌株在内的金黄色葡萄球菌及其他细菌的患儿中，诺氟沙星的有效率为88.0%。2. 空腹单次口服50毫克和100毫克诺氟沙星片剂后，血清浓度的平均峰值分别为0.35、0.48微克/毫升，半衰期分别为2.2、2.7小时。3. 每日剂量为4.6 - 35.7毫克/千克（最大每日600毫克）、疗程为3至19天的诺氟沙星治疗中，未出现提示关节病的不良反应。根据这些初步数据，诺氟沙星在儿童传染病治疗中似乎占有一席之地。
